EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inter‐institutional perspectives on usage of fibrinogen replacement therapies in North America

Cindy Tay iD, Laura K Dilly iD, Wen Lu iD, Kerry O'Brien iD, Hlaing Tint iD, Quentin Eichbaum iD

Vox Sanguinis · 15.09.2026

DOI: 10.1111/vox.70374 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vox Sanguinis, online erschienen am 15.09.2026. Verfasst von Cindy Tay und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Cryoprecipitated antihemophilic factor (cryoprecipitate), fibrinogen concentrate (FC), and pathogen‐reduced cryoprecipitated fibrinogen complex (PR cryoprecipitate) are sources of fibrinogen replacement, and each has advantages and disadvantages in terms of cost, efficacy, safety, and logistics of administration. This study examines the respective utilization frequencies of these different products at institutions in North America and the factors influencing the decision on which one(s) to adopt. Materials and Methods A survey was distributed via email to contacts for Advancement of Blood and Biotherapies (AABB)‐accredited blood banks/transfusion services. Survey questions covered topics including the availability and usage of FC, cryoprecipitate, and PR cryoprecipitate, as well as the perceived advantages of each product.

Results

A total of 53 responses were received from surveyed institutions (estimated 25% response rate). Over half (31/53, 58.5%) of respondents exclusively used cryoprecipitate, 30.2% (16/53) used two sources of fibrinogen replacement, and 7.5% (4/53) used all three (cryoprecipitate, FC, and PR cryoprecipitate). More than half of the institutions restricted FC to specific indications, primarily for cost containment. The most commonly cited advantages of FC over cryoprecipitate were storage convenience and rapid reconstitution.

Conclusion

Surveyed institutions in the United States and Canada primarily use cryoprecipitate for fibrinogen replacement, with variable usage of FC and limited usage of PR cryoprecipitate. The perception of FC being more expensive than cryoprecipitate predominated. Further studies comparing available fibrinogen replacement options would be valuable, particularly with consideration of product acquisition cost, wastage, impacts on utilization of other blood products, and patient outcomes.

Schlagwörter

Stichwörter der Autor:innen

cross‐sectional surveycryoprecipitate AHFfibrinogen concentratesfibrinogen replacementpathogen‐reduced cryoprecipitate

Autor:innen und Institutionen

  • Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Pathology, University of California San Diego, San Diego, California, USA.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Department of Pathology and Laboratory Medicine, McGovern Medical School, Houston, Texas, USA.
  • Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

ORCID-Profile: Cindy Tay, Laura K Dilly, Wen Lu, Kerry O'Brien, Hlaing Tint, Quentin Eichbaum

Zitieren

APA

Tay, C., Dilly, L. K., Lu, W., O'Brien, K., Tint, H., & Eichbaum, Q. (2026). Inter‐institutional perspectives on usage of fibrinogen replacement therapies in North America. Vox Sanguinis. https://doi.org/10.1111/vox.70374

Vancouver

Tay C, Dilly LK, Lu W, O'Brien K, Tint H, Eichbaum Q. Inter‐institutional perspectives on usage of fibrinogen replacement therapies in North America. Vox Sanguinis. 2026. doi:10.1111/vox.70374

BibTeX
@article{Tay2026,
  author = {Tay, Cindy and Dilly, Laura K and Lu, Wen and O'Brien, Kerry and Tint, Hlaing and Eichbaum, Quentin},
  title = {Inter‐institutional perspectives on usage of fibrinogen replacement therapies in North America},
  journal = {Vox Sanguinis},
  year = {2026},
  doi = {10.1111/vox.70374}
}
Kostenlos starten →